Trial · NCT07131280
National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis
NCT07131280, Not applicable, Not yet recruiting, Institute of Liver and Biliary Sciences, India
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis. Trials, record NCT07131280. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07131280
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis
- NCT number
- NCT07131280
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 110 participants, estimated
- Lead sponsor
- Institute of Liver and Biliary Sciences, India
- Conditions
- Decompensated Cirrhosis
- Interventions
- Gcsf, Darbepoetin, Standard Medical Treatment
- First posted
- 2025-08-20
- Last updated
- 2025-08-20
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Transplant-free survival of GCSF + darbepoetin in patients with early decompensated cirrhosis in both groups. | 3 year | |
| Secondary | Transplant-free survival | 6-month, one year, 2 year and 3 year | |
| Secondary | Proportion of patient developed new-onset of Liver Related Event (such as ascites, hepatic encephalopathy , acute kidney injury, bleed and sepsis) or show mortality in both the groups | 6-month, one year, 2 year and 3 year | |
| Secondary | Cumulative incidence of sepsis, acute kidney injury or secondary organ dysfunction in both groups | 6-month, one year, 2 year and 3 year | |
| Secondary | Cumulative incidence of second decompensation | 6-month, one year, 2 year and 3 year | |
| Secondary | Improvement in liver disease severity indices, including the Child-Turcotte-Pugh (CTP) score (ΔCTP). | 6-month, one year, 2 year and 3 year | |
| Secondary | Improvement in liver disease severity indice like Model for End-Stage Liver Disease (MELD) score (ΔMELD). | 6-month, one year, 2 year and 3 year | |
| Secondary | Proportion of patients completing treatment without major adverse effects | 6-month, one year, 2 year and 3 year | Adverse effects will be graded in accordance to CTCAE |
| Secondary | Impact on liver injury (assessed by AST and ALT levels in blood). | 6-month, one year, 2 year and 3 year | |
| Secondary | Impact on fibrosis (evaluated using Masson's Trichome stain and the Enhanced Liver Fibrosis [ELF] score). | 6-month, one year, 2 year and 3 year |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07131280
GET https://conductscience.org/api/trials/v1/NCT07131280/registered